ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
|
||
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
• | The world-wide market for medical imaging is large and it has a potential to expand in the areas where QT Imaging has differentiation: |
• | A non-ionizing, non-injection imaging |
• | A lower price point than conventional high-energy imaging equipment; |
• | QT Imaging technology can be deployed to LREs because of its low power, no shielding, no injection, and automation; |
• | QT Imaging technology is portable and can be used in POC settings such as LREs; and |
• | QT Imaging technology is deployable in outdoor settings such as sports, military, and naval settings. |
• | The QT Imaging technology is well-suited for lowering health care costs by being affordable and easily accessed. |
• | The QT Imaging technology is well-suited for DTC and DTP applications, that are outside traditional tertiary care hospitals. |
• | QT Imaging technology is uniquely proprietary, disruptive and a one-of-a kind |
• | QT Imaging products have potential strong revenue growth, with capital purchase or subscription-based recurring revenues supporting substantial long-term gross margin. |
• | Create disruptive innovation—a dedication to using technology (siliconization, software, artificial intelligence, and smart physics) to improve medical imaging and thus health care quality and access. |
• | Introduce the first comprehensive body-safe imaging technology into the marketplace, enabling for the first-time well-person body imaging health screening, and the first health screening medical imaging for infants. |
• | Provide DTC and DTP approaches to de-centralize medical imaging from the large, comprehensive medical centers; enabling the ability to lower health care costs and increase access via personal medical imaging. |
• | Provide a new social and economic opportunity for consumers to take control of some aspects of their own health care—such as imaging for minor injuries or medical conditions without needing a healthcare “gate-keeper.” |
• | Enable more patient and practitioner control—or “democratization” of healthcare using technology. |
• | Focus on patient-outcomes and customer success by using novel multi-channel go-to-market |
• | Focus our intellectual capabilities and ethical framework to become unified in our mission to improve the quality and lower the cost of health care world-wide . . . “It’s about time.” |
• | Subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and |
• | Cause us to depend on the marketing and sale of a single product or limited number of products or services. |
• | our being a development-stage company with limited operating history and significant losses; |
• | our ability to successfully execute our business model, including market acceptance of our planned products and product candidates at acceptable prices; |
• | our ability to sustain revenue growth or profitability; |
• | future financial performance following the proposed business combination; |
• | the ability to obtain clearances and approvals from the FDA for current and future products; |
• | the occurrence of a pandemic, epidemic, or outbreak of infectious disease that may materially or adversely affect our business, financials, and product development; |
• | our ability to compete and adapt in our industry; |
• | the ability of third-party manufacturers to supply certain components parts needed for our products; |
• | our plan to do business globally is subject to additional risks and uncertainties; |
• | the impact of recent changes in the United States related to payment policies for imaging procedures; |
• | the success of key supplier or distribution agreements; |
• | the outcome of any legal proceedings that may be instituted against our business and other litigation and regulatory risks; |
• | our success in recruiting and retaining key employees; |
• | our management team’s limited experience managing a public company; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business; |
• | the ability to maintain the confidentiality and integrity of the Company’s data and other sensitive information; |
• | the ability of the business to respond to changes in general economic conditions; |
• | our limited experience in working with large-scale contracts with medical device manufacturers; |
• | the ability to adequately protect the Company’s intellectual property rights; |
• | the impact of the terms and conditions of licenses and sublicenses granted by third-parties; |
• | our ability to enforce covenants not to compete; |
• | the ability to manage growth effectively; |
• | the effect of the Company’s warrants on the market price of its Common Stock; |
• | the effect of unanticipated changes in effective tax rates on operations and financials; |
• | factors relating to the business, operations and financial performance of the Combined Company; |
• | the ability of the Combined Company to maintain an effective system of internal controls over financial reporting; |
• | the impact of the COVID-19 pandemic; |
• | our being an emerging growth company; |
• | our governing documents’ effect on stock price and stockholders’ ability to gain favorable judicial forums; and |
• | the other risks and uncertainties discussed in “Risk Factors” and elsewhere in this Annual Report. |
• | effectiveness of the sales and marketing efforts of us, and our international distribution partners; |
• | perception by medical professionals and patients of the convenience, safety, efficiency and benefits of the QT Breast Scanner or products under development using our technology, compared to competing methods of medical imaging; |
• | opposition from certain industry leaders, which may limit our ability to promote the QT Breast Scanner or products under development that are cleared by the FDA and other regulatory agencies, or Medical Scan as a Service, and to penetrate into the medical imaging market in certain geographical areas; |
• | the level of commitment and support that we receive from our partners, such as cloud storage providers, as well as medical professionals such as radiologists; |
• | willingness of market participants to accept the Medical Scan as a Service model; |
• | the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic; |
• | timing of market introduction of competing products, and the sales and marketing initiatives of such products; |
• | press and blog coverage, social media coverage, and other publicity and public relations factors by others; |
• | lack of financing or other resources to successfully develop and commercialize our technology and implement our business plan; and |
• | coverage determinations and reimbursement levels of third-party payors. |
• | the process of manufacturing and deploying the QT Breast Scanner and our products under development is a complex, multi-step process that depends on factors outside our control, and could cause us to expend significant time and resources prior to earning associated revenues; |
• | the manufacturing cost of the QT Breast Scanner and our products under development may be higher than we expect, may increase significantly, or may increase at a higher rate than anticipated, and we may not be able to set or timely adjust our Medical Scan as a Service pricing to compensate for any increased costs; |
• | the manufacturing of the QT Breast Scanner and our future products may take longer than we expected, and we may have insufficient manufacturing capacity and experience delays in manufacturing and deployment, which would have a negative impact on the timing of our revenues; |
• | deployment and full utilization of the QT Breast Scanner may not be achieved if insurance and other reimbursements and patient co-pays are not sufficient to defray costs incurred in providing and interpreting scans by hospital imaging centers, cancer centers or other women’s health-care centers that purchase our devices and services, and we may not be able to sustain these relationships unless our devices can be profitable to these providers; |
• | a QT Breast Scanner device may perform fewer scans per day than our estimates due to a number of factors, including low market acceptance rate, technical failures and downtime, service disruptions, outages or other performance problems, which would have a negative impact on our revenues and our ability to recover costs; |
• | as part of the Medical Scan as a Service model, we will be responsible for maintenance of the QT Breast Scanner devices we deploy, which may be more costly and time-consuming than we expect; |
• | our customers may not be able to find or retain a sufficient number of radiologists to review the images generated by the QT Breast Scanner device especially as we deploy additional systems and the volume of scans increases; |
• | our Medical Scan as a Service pricing may not be sufficient to recover our costs and may not be adjusted in a timely manner, which could negatively affect our revenues or cause our revenues and results of operations to vary significantly from period to period; |
• | we have not determined a target price per scan, and when we do, we may be unsuccessful in maintaining our target price because we do not control the price charged by local operators and higher prices may adversely affect market acceptance of the QT Breast Scanner device; and |
• | regulatory authorities may challenge our Medical Scan as a Service model altogether, and impose significant civil, criminal, and administrative penalties, damages, fines, and/or exclusion from government funded healthcare programs, which could adversely affect our revenues and results of operations. |
• | our inability to achieve sufficient market acceptance by hospitals and clinics, providers of medical imaging services, medical professionals such as radiologists, third-party payors, and others in the medical community; |
• | our inability to compete with existing medical imaging technology companies with ultrasound, mammography and magnetic resonance imaging (“ MRI |
• | our inability to hire, train and retain qualified sales and marketing personnel; |
• | our inability to establish, maintain and expand our sales, marketing and distribution networks; |
• | our inability to obtain and/or maintain necessary regulatory approvals; and |
• | our inability to effectively protect our intellectual property. |
• | “The QT Breast Scanner is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The QT Breast Scanner software also calculates the breast fibroglandular volume and total breast volume. The device is not intended to be used as a replacement for screening mammography”—FDA 510k K162372 and K220933 |
• | “The QT Breast Scanner Model 2000A satisfies the requirements of the Certification Mark of the ECM [CE Mark Certification of the European Union]—No. 0P210730.QTUTQ02” |
• | insufficient capacity or delays in meeting our demand; |
• | inadequate manufacturing yields, inferior quality and excessive costs; |
• | inability to manufacture products that meet the agreed upon specifications; |
• | inability to obtain an adequate supply of materials; |
• | inability to comply with the relevant regulatory requirements for the manufacturing process; |
• | limited warranties on products supplied to us; |
• | inability to comply with our contractual obligations; |
• | potential increases in prices; and |
• | increased exposure to potential misappropriation of our intellectual property. |
• | reimbursement and insurance coverage; |
• | our inability to find agencies, dealers or distributors in specific countries or regions; |
• | our inability to directly control commercial activities of third parties; |
• | limited resources to be deployed to a specific jurisdiction; |
• | the burden of complying with complex and changing regulatory, tax, accounting and legal requirements; |
• | different medical imaging practice and customs in foreign countries affecting acceptance in the marketplace; |
• | import or export licensing and other requirements that could impair our ability to compete in international markets or subject our company to liability if we violate such laws and regulations; |
• | longer accounts receivable collection times; |
• | longer lead times for shipping; |
• | language barriers for technical training; |
• | reduced protection of intellectual property rights in some foreign countries; |
• | foreign currency exchange rate fluctuations; and |
• | interpretations of contractual provisions governed by foreign laws in the event of a contract dispute. |
• | limiting payments for imaging services in physician offices and free-standing imaging facility settings based upon rates paid to hospital outpatient departments; |
• | reducing payments for certain imaging procedures when performed together with other imaging procedures in the same family of procedures on the same patient on the same day in the physician office and free-standing imaging facility setting; |
• | making significant revisions to the methodology for determining the practice expense component of the Medicare payment applicable to the physician office and free-standing imaging facility setting which results in a reduction in payment; and |
• | revising payment policies and reducing payment amounts for imaging procedures performed in the hospital outpatient setting. |
• | disputes among payors as to which party is responsible for payment; |
• | disparity in coverage among various payors; |
• | disparity in information and billing requirements among payors; and |
• | incorrect or missing billing information, which is required to be provided by the ordering physician. |
• | we may not be able to control the amount and timing of resources that our collaborators may devote to our technology; |
• | should a collaborator fail to comply with applicable laws, rules or regulations when performing services for us, we could be held liable for such violations; |
• | our collaborators may have a shortage of qualified personnel, particularly radiologists who can review the medical images generated by the QT Breast Scanner and products and services under development including the Medical Scan as a Service, especially as we deploy additional devices and new products and the volume of scans increases; |
• | we may be required to relinquish important rights, such as marketing and distribution rights; |
• | business combinations or significant changes in a collaborator’s business strategy may adversely affect a collaborator’s willingness or ability to complete its obligations under any arrangement; |
• | under certain circumstances, a collaborator could move forward with a competing product developed either independently or in collaboration with others, including our competitors; |
• | our current or future collaborators may utilize our proprietary information in a way that could expose us to competitive harm; |
• | our collaborators could obtain ownership or other control over intellectual property that is material to our business; and |
• | collaborative arrangements are often terminated or allowed to expire, which could delay the ability to commercialize our technology. |
• | our ability to provide incremental clinical and economic data that shows the safety and clinical efficacy and cost-effectiveness of, and patient benefits from, our products; |
• | the availability of alternative products; |
• | whether our products or the use thereof are included on insurance company formularies or coverage plans; |
• | the willingness and ability of patients and the healthcare community to adopt our technologies; |
• | customer demand; |
• | liability risks generally associated with the use of new product candidates; |
• | the training required to use a new product candidates; |
• | perceived inadequacy of evidence supporting clinical benefits or cost-effectiveness over existing alternatives; |
• | the convenience and ease of use of our products relative to other treatment methods; |
• | the pricing and reimbursement of our products relative to other treatment methods; and |
• | the marketing and distribution support for our products. |
• | injury to our reputation; |
• | costs of related litigation and substantial monetary awards to patients and others; |
• | decreased demand for our products and services; |
• | loss of revenue; and |
• | the inability to commercialize future products. |
• | our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our product candidates are safe or effective for their intended uses; |
• | the disagreement of the FDA or the applicable foreign regulatory body with the design or implementation of our clinical trials or the interpretation of data from pre-clinical studies or clinical trials; |
• | serious and unexpected adverse effects experienced by participants in our clinical trials; |
• | the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; |
• | our inability to demonstrate that the clinical and other benefits of the device outweigh the risks; |
• | the manufacturing process or facilities we use may not meet applicable requirements; and |
• | the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval. |
• | untitled letters or warning letters; |
• | fines, injunctions, consent decrees and civil penalties; |
• | recalls, termination of distribution, administrative detention, or seizure of our products; |
• | customer notifications or repair, replacement or refunds; |
• | operating restrictions or partial suspension or total shutdown of production; |
• | delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products; |
• | withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products; |
• | FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and |
• | criminal prosecution. |
• | The U.S. federal healthcare program Anti-Kickback Statute (the “ Anti-Kickback Statute |
and regulatory safe harbors available, and the range of interpretations to which they are subject, it is possible that some of our current or future practices might be challenged under one or more of these laws, including, without limitation, our Medical Scan as a Service model. QT Imaging’s compliance with Medicare and Medicaid regulations may be reviewed by federal or state agencies, including the OIG, CMS, and the U.S. Department of Justice, or may be subject to whistleblower lawsuits under federal and state false claims laws. |
• | The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. In recent years, several healthcare companies have faced enforcement actions under the federal False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product or causing false claims to be submitted because of the company’s marketing the product for unapproved, and thus non-reimbursable, uses. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of tens of thousands of dollars per false claim or statement. Healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs. |
• | The Health Insurance Portability and Accountability Act of 1996 (“ HIPAA HITECH |
• | The Physician Payment Sunshine Act, implemented as the Open Payments program, requires manufacturers of certain products reimbursed by Medicare, Medicaid, or the Children’s Health Insurance Program to track and report to the federal government payments and transfers of value that they make to physicians and teaching hospitals, certain other healthcare professionals beginning in 2022, group purchasing organizations, and ownership interests held by physicians and their families, and provides for public disclosures of these data. Manufacturers are required to submit annual reports to the government and failure to do so may result in civil monetary penalties for all payments, transfers of value and ownership or investment interests not reported in an annual submission, and may result in liability under other federal laws and regulations. |
• | Many states have adopted laws and regulations analogous to the federal laws cited above, including state anti-kickback and false claims laws, which may apply to items or services reimbursed under Medicaid and other state programs or, in several states, regardless of the payer. Several states have enacted legislation requiring medical device companies to, among other things, establish marketing compliance programs; file periodic reports with the state, including reports on gifts and payments to individual health care providers; make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities; and/or register their sales representatives. Some states prohibit specified sales and marketing practices, including the provision of gifts, meals, or other items to certain health care providers. |
• | strengthen the rules on placing devices on the market and reinforce surveillance once they are available; |
• | establish explicit provisions on manufacturers’ responsibilities for follow-up regarding the quality, performance and safety of devices placed on the market; |
• | improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; |
• | set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and |
• | strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market. |
• | Imposes an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, which, through a series of legislative amendments, was suspended, effective January 1, 2016 and subsequently repealed altogether on December 20, 2019; |
• | Establishes a new Patient-Centered Outcomes Research Institute to oversee and identify priorities in comparative clinical effectiveness research in an effort to coordinate and develop such research; and |
• | Implements Medicare payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. |
• | inability to retain adequate numbers of effective sales and marketing personnel; |
• | the lack of complementary products and services to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and |
• | unforeseen costs and expenses associated with creating an independent sales and marketing organization; |
• | generate widespread awareness, acceptance and adoption of our technology and future products or services; |
• | develop new or enhanced technologies or features that improve the convenience, efficiency, safety or perceived safety, and productivity of our technology and future products or services; |
• | properly identify customer needs and deliver new products or services or product enhancements to address those needs; |
• | limit the time required from prototype development to commercial production; |
• | limit the timing and cost of regulatory approvals; |
• | attract and retain qualified personnel and collaborators; |
• | protect our inventions with patents or otherwise develop proprietary products and processes; and |
• | secure sufficient capital resources to expand both our continued research and development, and sales and marketing efforts. |
• | changes in the valuation of our deferred tax assets and liabilities; |
• | expected timing and amount of the release of any tax valuation allowances; |
• | tax effects of stock-based compensation; |
• | costs related to intercompany restructurings; |
• | changes in tax laws, regulations or interpretations thereof; or |
• | lower than anticipated future earnings in jurisdictions where we have lower statutory tax rates and higher than anticipated future earnings in jurisdictions where we have higher statutory tax rates. |
• | the impact of the COVID-19 pandemic on our financial condition and the results of operations; |
• | our operating and financial performance and prospects; |
• | quarterly or annual earnings or those of other companies in our industry compared to market expectations; |
• | conditions that impact demand for our products and/or services; |
• | future announcements concerning our business, our clients’ businesses or our competitors’ businesses; |
• | the public’s reaction to our press releases, other public announcements and filings with the SEC; |
• | the market’s reaction to our reduced disclosure and other requirements as a result of being an “emerging growth company” under the Jumpstart Our Business Startups Act (the “ JOBS Act |
• | the size of our public float; |
• | coverage by or changes in financial estimates by securities analysts or failure to meet their expectations; |
• | market and industry perception of our success, or lack thereof, in pursuing our growth strategy; |
• | strategic actions by us or our competitors, such as acquisitions or restructurings; |
• | changes in laws or regulations which adversely affect our industry or us; |
• | privacy and data protection laws, privacy or data breaches, or the loss of data; |
• | changes in accounting standards, policies, guidance, interpretations or principles; |
• | changes in senior management or key personnel; |
• | issuances, exchanges or sales, or expected issuances, exchanges or sales of our capital stock; |
• | changes in our dividend policy; |
• | adverse resolution of new or pending litigation against us; and |
• | changes in general market, economic and political conditions in the United States and global economies or financial markets, including those resulting from natural disasters, terrorist attacks, acts of war and responses to such events. |
• | a staggered board, which means that the Combined Company Board is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for cause; |
• | limitations on convening special stockholder meetings, which could make it difficult for our stockholders to adopt desired governance changes; |
• | prohibition on stockholder action by written consent, which means that our stockholders are only able to take action at a meeting of stockholders and are not able to take action by written consent for any matter; |
• | a forum selection clause, which means certain litigation against us can only be brought in Delaware; |
• | the authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without further action by our stockholders; and |
• | advance notice procedures, which apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders. |
Units (GIAFU) |
Warrants (GIAFW) |
|||||||||||||||
High |
Low |
High |
Low |
|||||||||||||
Year Ended December 31, 2023 |
||||||||||||||||
Quarter ended March 31, 2023 |
$ | 11.00 | $ | 10.24 | $ | 0.04 | $ | 0.02 | ||||||||
Quarter ended June 30, 2023 |
$ | 10.65 | $ | 2.03 | $ | 0.03 | $ | 0.01 | ||||||||
Quarter ended September 30, 2023 |
$ | 10.49 | $ | 10.49 | $ | 0.04 | $ | — | ||||||||
Quarter ended December 31, 2023 |
$ | 10.49 | $ | 10.49 | $ | 0.05 | $ | 0.01 |
• | may significantly dilute the equity interest of investors in the Offering who would not have pre-emption rights in respect of any such issue; |
• | may subordinate the rights of holders of common stock if the rights, preferences, designations and limitations attaching to the preferred shares are senior to those afforded our shares of common stock; |
• | could cause a change in control if a substantial number of shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors; |
• | may have the effect of delaying or preventing a change of control of us by diluting the share ownership or voting rights of a person seeking to obtain control of us; and |
• | may adversely affect prevailing market prices for our shares of common stock. |
• | default and foreclosure on our assets if our operating revenues after our initial business combination are insufficient to repay our debt obligations; |
• | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
• | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
• | our inability to obtain necessary additional financing if any document governing such debt contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
• | our inability to pay dividends on our shares of common stock; |
• | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes; |
• | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
• | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
• | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt. |
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Common stock subject to possible redemption |
||||||||
Numerator: Earnings allocable to common stock subject to redemption |
||||||||
Interest earned on marketable securities held in Trust Account, net of taxes |
$ | 1,107,741 | $ | 1,143,783 | ||||
Net income attributable to common stock subject to possible redemptions |
$ | 1,107,741 | $ | 1,143,783 | ||||
Denominator: Weighted-average common shares subject to redemption |
||||||||
Basic and diluted weighted-average shares outstanding, common stock subject to possible redemption |
3,020,634 | 17,954,419 | ||||||
Basic and diluted net income per share, common stock subject to possible redemption |
$ | 0.37 | $ | 0.06 | ||||
Non-Redeemable common stock |
||||||||
Numerator: Net loss minus net earnings - Basic and diluted |
||||||||
Net loss |
$ | (4,024,591 | ) | $ | (2,774,307 | ) | ||
Less: net income attributable to common stock subject to redemption |
(1,107,741 | ) | (1,143,783 | ) | ||||
Net loss attributable to non-redeemable common stock |
$ | (5,132,332 | ) | $ | (3,918,090 | ) | ||
Denominator: Weighted-average non-redeemable common shares |
||||||||
Weighted-average non-redeemable common shares outstanding, basic and diluted |
6,540,000 | 6,540,000 | ||||||
Net loss per share, non-redeemable common stock, basic and diluted |
$ | (0.78 | ) | $ | (0.60 | ) | ||
8 0 |
||||
8 1 |
||||
8 2 |
||||
8 3 |
||||
8 4 |
||||
8 5 |
December 31, 2023 |
December 31, 2022 |
|||||||
ASSETS |
||||||||
Current assets |
||||||||
Cash |
$ | $ | ||||||
Prepaid expenses and other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
Cash and marketable securities held in Trust Account |
||||||||
Interest receivable on cash and marketable securities held in the Trust Account |
||||||||
|
|
|
|
|||||
TOTAL ASSETS |
$ | $ | ||||||
|
|
|
|
|||||
LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT |
||||||||
Current liabilities |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued legal fees |
||||||||
Accrued liabilities |
||||||||
Payable to related parties |
||||||||
Note payable to related party |
||||||||
Note payable to related party at fair value |
||||||||
Other current liabilities |
||||||||
Deferred underwriting fee payable - current |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
Warrant liability |
||||||||
Deferred underwriting fee payable |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
Commitments and contingencies (Note 6) |
||||||||
Common stock subject to possible redemption, |
||||||||
|
|
|
|
|||||
Stockholders’ deficit |
||||||||
Preferred stock, par value of $ |
||||||||
Common stock, par value of $ 3 and 2022 |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) |
( |
) | ||||
|
|
|
|
|||||
Total stockholders’ deficit |
( |
) | ( |
) | ||||
|
|
|
|
|||||
TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Revenues |
$ |
$ |
||||||
General and administrative expenses |
||||||||
|
|
|
|
|||||
Loss from operations |
( |
) | ( |
) | ||||
Other income (expense) |
||||||||
Other income |
||||||||
Interest expense |
( |
) |
( |
) | ||||
Interest income on cash and marketable securities held in Trust Account |
||||||||
|
|
|
|
|||||
Loss before provision for income taxes |
( |
) | ( |
) | ||||
Provision for income taxes |
||||||||
|
|
|
|
|||||
Net loss and comprehensive loss |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Net income attributable to common stock subject to possible redemption |
$ | $ | ||||||
|
|
|
|
|||||
Basic and diluted weighted-average shares outstanding, common stock subject to possible redemption |
||||||||
|
|
|
|
|||||
Basic and diluted net income per share, common stock subject to possible redemption |
$ | $ | ||||||
|
|
|
|
|||||
Net loss attributable to common stockholders |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
|||||
Weighted-average common shares outstanding, basic and diluted |
||||||||
|
|
|
|
|||||
Net loss per share common share, basic and diluted |
$ | ( |
) | $ | ( |
) | ||
|
|
|
|
Common Stock |
Additional Paid- InCapital |
|||||||||||||||||||
Shares |
Amount |
Accumulated Deficit |
Stockholders’ Deficit |
|||||||||||||||||
Balance as of January 1, 2022 |
$ |
$ |
$ |
( |
) | $ |
( |
) | ||||||||||||
Debt discount on note payable to related party |
— | — | — | |||||||||||||||||
Shares subject to redemption |
— | — | ( |
) | — | ( |
) | |||||||||||||
Reclass of negative additional paid-in capital to accumulated deficit |
— | — | ( |
) | — | |||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of December 31, 2022 |
( |
) | ( |
) | ||||||||||||||||
Debt discount on note payable to related party |
— | — | — | |||||||||||||||||
Excise tax liability accrued for common stock redemptions |
|
|
— |
|
|
|
— |
|
|
|
( |
) |
|
|
— |
|
|
|
( |
) |
Shares subject to redemption |
— | — | ( |
) | — | ( |
) | |||||||||||||
Adjustment to deferred underwriting fees |
— | — | — | |||||||||||||||||
Net loss |
— | — | — | ( |
) | ( |
) | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Balance as of December 31, 2023 |
$ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
OPERATING ACTIVITIES |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
Change in fair value of warrant liability and related party note |
( |
) | ( |
) | ||||
Interest earned on cash and marketable securities held in Trust Account |
( |
) | ( |
) | ||||
Amortization on debt discount on note payable to related party |
||||||||
Change in operating assets and liabilities: |
||||||||
Prepaid expenses and other current assets |
||||||||
Other long-term assets |
||||||||
Payable to related parties |
||||||||
Accounts payable |
||||||||
Accrued legal fees |
||||||||
Accrued liabilities |
( |
) | ||||||
Other current liabilities |
( |
) | ||||||
|
|
|
|
|||||
Net cash used in operating activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
INVESTING ACTIVITIES |
||||||||
Investm en t of cash in Trust Account, net |
( |
) | ( |
) | ||||
Cash withdrawn from Trust Account |
||||||||
|
|
|
|
|||||
Net cash provided by investing activities |
||||||||
|
|
|
|
|||||
FINANCING ACTIVITIES |
||||||||
Borrowings from related parties |
||||||||
Borrowings from related parties at fair value |
||||||||
Redemption of Public Units |
( |
) | ( |
) | ||||
Payment of offering costs |
( |
) | ||||||
|
|
|
|
|||||
Net cash used in financing activities |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Net decrease in cash during period |
( |
) | ( |
) | ||||
Cash, beginning of period |
||||||||
|
|
|
|
|||||
Cash, end of period |
$ | $ | ||||||
|
|
|
|
|||||
SUPPLEMENTAL DISCLOSURES |
||||||||
Cash paid for income taxes |
$ | $ | ||||||
|
|
|
|
|||||
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES |
||||||||
Change in value of common stock subject to possible redemption |
$ | $ | ||||||
|
|
|
|
|||||
Excise tax liability accrued for stock redemptions |
$ | $ | ||||||
|
|
|
|
|||||
Waiver of deferred underwriting fees |
$ | $ |
||||||
|
|
|
|
|||||
Debt discount on note payable to related party |
$ | $ | ||||||
|
|
|
|
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Common stock subject to possible redemption |
||||||||
Numerator: Earnings allocable to common stock subject to redemption |
||||||||
Interest earned on marketable securities held in Trust Account, net of taxes |
$ | $ | ||||||
Net income attributable to common stock subject to possible redemptions |
$ | $ | ||||||
Denominator: Weighted-average common shares subject to redemption |
||||||||
Basic and diluted weighted-average shares outstanding, common stock subject to possible redemption |
||||||||
Basic and diluted net income per share, common stock subject to possible redemption |
$ | $ | ||||||
Non-Redeemable common stock |
||||||||
Numerator: Net loss minus net earnings - Basic and diluted |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Less: net income attributable to common stock subject to redemption |
( |
) | ( |
) | ||||
Net loss attributable to non-redeemable common stock |
$ | ( |
) | $ | ( |
) | ||
Denominator: Weighted-average non-redeemable common shares |
||||||||
Weighted-average non-redeemable common shares outstanding, basic and diluted |
||||||||
Net loss per share, non-redeemable common stock, basic and diluted |
$ | ( |
) | $ | ( |
) | ||
Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. | |
Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. | |
Level 3: | Unobservable inputs which are supported by little or no market activity and which are significant to the fair value of the assets or liabilities. |
Description: |
Level |
December 31, 2023 |
December 31, 2022 |
|||||||||
Assets: |
||||||||||||
M arketable securities held in Trust Account |
1 | $ | $ | |||||||||
|
|
|
|
|||||||||
Liabilities: |
||||||||||||
Warrant liability |
2 | $ | $ | |||||||||
|
|
|
|
|||||||||
Note payable to related party at fair value |
3 | $ | $ | |||||||||
|
|
|
|
Assumptions |
At Issuance |
As of December 31, 2023 |
As of December 31, 2022 | |||
Expected term |
||||||
Volatility |
||||||
Risk free rate |
||||||
Discount rate |
% - | |||||
Probability of conversion |
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Fair value - beginning of period |
$ | $ |
||||||
Additions |
||||||||
Change in fair value |
( |
) | ||||||
Fair value - en d of period |
$ | $ |
||||||
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Domestic |
$ | ( |
) |
$ | ( |
) | ||
Foreign |
— | — | ||||||
Total |
$ | ( |
) | $ | ( |
) | ||
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Current: |
||||||||
Federal |
$ | $ | ||||||
State and local |
||||||||
Foreign |
— | — | ||||||
Total current |
||||||||
Deferred: |
||||||||
Federal |
— | — | ||||||
State and local |
— | — | ||||||
Foreign |
— | — | ||||||
Total deferred |
— | — | ||||||
Total provision for income taxes |
$ | $ | ||||||
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Statutory income tax benefit |
$ | ( |
) |
$ | ( |
) | ||
State income taxes, net of federal |
( |
) | ( |
) | ||||
Warrant and note payable revaluation |
( |
) | ||||||
Valuation allowance on start-up costs |
||||||||
Provision for income taxes |
$ | $ | ||||||
December 31, 2023 |
December 31, 2022 |
|||||||
Deferred tax assets: |
||||||||
Start-up costs |
$ | $ | ||||||
Valuation allowance |
( |
) |
( |
) | ||||
Net deferred tax assets (liabilities) |
$ | — | $ | — | ||||
Name |
Age |
Position | ||
Dr. Avi S. Katz | 65 | Executive Chairman of the Board of Directors | ||
Dr. Raluca Dinu | 50 | Director, President, Chief Executive Officer and Secretary | ||
Dorothy D. Hayes | 73 | Director | ||
Karen Rogge | 68 | Director | ||
Raanan I. Horowitz | 63 | Director | ||
Brad Weightman | 69 | Treasurer and Chief Financial Officer |
• | assisting the Board of Directors in the oversight of (1) the accounting and financial reporting processes of the Company and the audits of the financial statements of the Company, (2) the preparation and integrity of the financial statements of the Company, (3) the compliance by the Company with financial statement and regulatory requirements, (4) the performance of the Company’s internal finance and accounting personnel and its independent registered public accounting firm, and (5) the qualifications and independence of the Company’s independent registered public accounting firm; |
• | reviewing with each of the internal auditors and independent registered public accounting firm the overall scope and plans for audits, including authority and organizational reporting lines and adequacy of staffing and compensation. |
• | reviewing and discussing with management and internal auditors the Company’s system of internal control and discussing with the independent registered public accounting firm any significant matters regarding internal controls over financial reporting that have come to its attention during the conduct of its audit; |
• | reviewing and discussing with management, internal auditors and the independent registered public accounting firm the Company’s financial and critical accounting practices, and policies relating to risk assessment and management; |
• | receiving and reviewing reports of the independent registered public accounting firm discussing 1) all critical accounting policies and practices to be used in the independent registered public accounting firm’s audit of the Company’s financial statements, 2) all alternative treatments of financial information within GAAP that have been discussed with management, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent registered public accounting firm, and 3) other material written communications between the independent registered public accounting firm and management, such as any management letter or schedule of unadjusted differences; |
• | reviewing and discussing with management and the independent registered public accounting firm the annual and quarterly financial statements and section entitled “ Management’s Discussion and Analysis of Financial Conditions and Results of Operations 10-K and Quarterly Reports on Form 10-Q; |
• | reviewing, or establishing, standards for the type of information and the type of presentation of such information to be included in, earnings press releases and earnings guidance provided to analysts and rating agencies; |
• | discussing with management and the independent registered public accounting firm any changes in Company’s critical accounting principles and the effects of alternative GAAP methods, off-balance sheet structures and regulatory and accounting initiatives; |
• | reviewing material pending legal proceedings involving the Company and other contingent liabilities; |
• | meeting periodically with the Chief Executive Officer, Chief Financial Officer, the senior internal auditing executive and the independent registered public accounting firm in separate executive sessions to discuss results of examinations; |
• | reviewing and approving all transactions between the Company and related parties or affiliates of the officers of the Company requiring disclosure under Item 404 of Regulation S-K prior to the Company entering into such transactions; |
• | establishing procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submissions by employees or contractors of concerns regarding questionable accounting or accounting matters; |
• | reviewing periodically with the Company’s management, independent registered public accounting firm and outside legal counsel (i) legal and regulatory matters which may have a material effect on the financial statements, and (ii) corporate compliance policies or codes of conduct, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding the Company’s financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities; and |
• | establishing policies for the hiring of employees and former employees of the independent registered public accounting firm. |
• | reviewing the performance of the Chief Executive Officer and executive management; |
• | assisting the Board of Directors in developing and evaluating potential candidates for executive positions (including Chief Executive Officer); |
• | reviewing and approving goals and objectives relevant to the Chief Executive Officer and other executive officer compensation, evaluate the Chief Executive Officer’s and other executive officers’ performance in light of these corporate goals and objectives, and set Chief Executive Officer and other executive officer compensation levels consistent with its evaluation and the company philosophy; |
• | approving the salaries, bonus and other compensation for all executive officers; |
• | reviewing and approving compensation packages for new corporate officers and termination packages for corporate officers as requested by management; |
• | reviewing and discussing with the Board of Directors and senior officers plans for officer development and corporate succession plans for the Chief Executive Officer and other senior officers; |
• | reviewing and making recommendations concerning executive compensation policies and plans; |
• | reviewing and recommending to the Board of Directors the adoption of or changes to the compensation of the Company’s directors; |
• | reviewing and approving the awards made under any executive officer bonus plan, and provide an appropriate report to the Board of Directors; |
• | reviewing and making recommendations concerning long-term incentive compensation plans, including the use of stock options and other equity-based plans, and, except as otherwise delegated by the Board of Directors, acting on as the “Plan Administrator” for equity-based and employee benefit plans; |
• | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for the Company’s executive officers and employees; |
• | reviewing periodic reports from management on matters relating to the Company’s personnel appointments and practices; |
• | assisting management in complying with the Company’s proxy statement and annual report disclosure requirements; |
• | issuing an annual report of the Compensation Committee on Executive Compensation for the Company’s annual proxy statement in compliance with applicable SEC rules and regulations; |
• | annually evaluating the Committee’s performance and the committee’s charter and recommending to the Board of Directors any proposed changes to the charter or the committee; and |
• | undertaking all further actions and discharge all further responsibilities imposed upon the Committee from time to time by the Board of Directors, the federal securities laws or the rules and regulations of the SEC. |
• | developing and recommending to the Board of Directors the criteria for appointment as a director; |
• | identifying, considering, recruiting and recommending candidates to fill new positions on the Board of Directors; |
• | reviewing candidates recommended by stockholders; |
• | conducting the appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates; and |
• | recommending director nominees for approval by the Board of Directors and election by the stockholders at the next annual meeting. |
• | None of our management team is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities. |
• | In the course of their other business activities, our Sponsor and management team may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. However, our management teams have agreed to present to us all suitable target business opportunities, subject to any fiduciary or contractual obligations. |
• | Unless we consummate our initial business combination, our management team and Sponsor will not receive reimbursement for any out-of-pocket |
• | The Founder Shares and Private Placement Shares will be released from lockup only if an initial business combination is successfully completed, and the private warrants and private rights will expire worthless if an initial business combination is not consummated. For the foregoing reasons, our board may have a conflict of interest in determining whether a particular target business is appropriate for effecting an initial business combination. |
• | Drs. Katz and Dinu, our independent directors, which are a married couple, Mr. Horowitz and Ms. Hayes, and Mr. Weightman, our Treasurer and Chief Financial Officer, each has a financial/voting interest in our Sponsor that entitles each of them to participate in any economic return that the Sponsor receives for its investment in the Company in accordance with terms negotiated with the other holders of financial/voting interests in our Sponsor. |
• | the corporation could financially undertake the opportunity; |
• | the opportunity is within the corporation’s line of business; and |
• | it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation. |
Individual |
Entity |
Entity’s Business |
Affiliation | |||
Dr. Avi S. Katz | GigFounders, LLC |
Consulting and Investment |
Founder and managing member | |||
GIG4L, LLC | Investment | Co-Founder and managing member | ||||
GigManagement, LLC | Management Company | Founder and managing member | ||||
GigAcquisitions, LLC | PPE (SPAC) sponsorship | Founder and manager | ||||
GigAcquisitions2, LLC | PPE (SPAC) sponsorship | Founder and manager | ||||
UpHealth, Inc. | Digital Healthcare | Chairman of Board of Directors | ||||
GigAcquisitions3, LLC | PPE (SPAC) sponsorship | Founder and manager | ||||
GigAcquisitions4, LLC | PPE (SPAC) sponsorship | Founder and manager | ||||
BigBear.ai Holdings, Inc. | Artificial Intelligence | Director | ||||
GigAcquisitions5, LLC | PPE (SPAC) sponsorship | Founder and manager | ||||
Dr. Raluca Dinu | UpHealth, Inc. | Digital Healthcare | Director | |||
BigBear.ai Holdings, Inc. | Artificial Intelligence | Director | ||||
GigManagement, LLC | Management Company | Founder and managing member | ||||
GIG4L, LLC | Investment | Co-Founder and managing member | ||||
Dorothy D. Hayes | First Tech Federal Credit Union | Credit Union | Director | |||
Intevac, Inc. | Thin Film Processing Equipment | Director and Chair of the Audit Committee | ||||
CoGenerate (formerlyEncore.org) | Innovation Nonprofit | Director | ||||
BigBear.ai Holdings, Inc. | Artificial Intelligence | Director and Chair of the Audit Committee | ||||
Karen Rogge (1) | Onto Innovation, Inc. | Semiconduction Equipment | Director | |||
RYN Group, LLC | Management Consulting | President | ||||
Raanan I. Horowitz | Elbit Systems of America | Defense and Aviation | Chief Executive Officer and Director | |||
BigBear.ai Holdings, Inc. | Artificial Intelligence | Director |
(1) | Karen Rogge was appointed to the board on February 7, 2023. |
Director |
Quarterly Compensation |
|||
Dr. Avi Katz |
$ | 30,000 | ||
Dr. Raluca Dinu |
$ | 30,000 | ||
Dorothy D. Hayes |
$ | 15,000 | ||
Raanan I. Horowitz |
$ | 12,000 | ||
Karen Rogge |
$ | — |
Name and principal position |
Year |
Salary |
Bonus |
Stock Awards |
Option Awards |
Nonequity incentive plan compensation |
Nonqualified deferred compensation earnings |
All other compensation (1) |
Total |
|||||||||||||||||||||||||
Dr. Avi S. Katz, Executive Chairman of the Board of Directors (Principal Executive Officer) |
January 1, 2023 through December 31, 2023 | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ | 120,000 | $ | 120,000 | |||||||||||||||||
Dr. Raluca Dinu, Director, President, Chief Executive Officer and Secretary (Principal Executive Officer) |
January 1, 2023 through December 31, 2023 | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ | 120,000 | $ | 120,000 | |||||||||||||||||
Brad Weightman, Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) |
January 1, 2023 through December 31, 2023 | $ | 180,000 | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | $ | 180,000 |
(1) | Advisory fees to be paid to directors for board committee service and administrative and analytical services, including certain activities on the Company’s behalf, such as identifying and investigating possible business targets and business combinations. All such amounts were unpaid as of December 31, 2023. |
Name |
Fees earned or paid in cash |
Stock Awards |
Option Awards |
Nonequity incentive plan compensation |
Change in pension value and nonqualified deferred compensation earnings |
All other compensation (1) |
Total |
|||||||||||||||||||||
Dorothy D. Hayes, Independent Director and Chairwoman of the Audit Committee |
$ | — | $ | — | $ | — | $ | — | $ | — | $ | 60,000 | $ | 60,000 | ||||||||||||||
Raanan I. Horowitz, Independent Director and Chairman of the Nominating and Corporate Governance Committee |
$ | — | $ | — | $ | — | $ | — | $ | — | $ | 48,000 | $ | 48,000 |
(1) | Advisory fees were paid to directors for board committee service and administrative and analytical services, including certain activities on the Company’s behalf, such as identifying and investigating possible business targets and business combinations. All such amounts were unpaid as of December 31, 2023. |
• | each person known by us to be the beneficial owner of more than 5% of the outstanding shares of common stock prior to the closing of the Business Combination; |
• | each of our directors and executive officers as of immediately prior to the closing of the Business Combination; and |
• | all directors and executive officers as a group as of immediately prior to the closing of the Business Combination. |
Name and Address of Beneficial Owner (1) |
Number of Shares Beneficially Owned |
Approximate Percentage of Outstanding Common Stock (2) |
||||||
GigAcquisitions5, LLC (3) |
6,530,000 | (4) |
75.4 | % | ||||
Dr. Avi S. Katz (3) |
6,530,000 | (4) |
75.4 | % | ||||
Dr. Raluca Dinu |
— | — | ||||||
Dorothy D. Hayes |
— | — | ||||||
Karen Rogge |
— | — | ||||||
Raanan I. Horowitz |
— | — | ||||||
Brad Weightman |
— | — | ||||||
All directors and officers as a group prior to the business combination (6 individuals) |
6,530,000 | 75.4 | % |
* | Less than one percent |
(1) | Unless otherwise indicated, the business address of each of the individuals is 1731 Embarcadero Rd., Suite 200, Palo Alto, CA 94303. |
(2) | Based on 8,657,593 shares of common stock outstanding as of December 31, 2023. |
(3) | Represents shares held by our Sponsor. The shares held by our Sponsor are beneficially owned by Dr. Avi S. Katz, our Executive Chairman, Secretary, President, and Chief Executive Officer, and the manager of our Sponsor, who has sole voting and dispositive power over the shares held by our Sponsor. |
(4) | Include 795,000 shares of common stock underlying Private Placement Units. |
Year Ended December 31, 2023 |
Year Ended December 31, 2022 |
|||||||
Audit Fees (1) |
$ | 337,666 | $ | 87,740 | ||||
Audit-Related Fees (2) |
— | — | ||||||
Tax Fees (3) |
|
— |
|
7,800 | ||||
All Other Fees (4) |
— | — | ||||||
Total |
$ | 337,666 | $ | 95,540 | ||||
(1) | Audit Fees. Audit fees consist of fees billed and to be billed for professional services rendered for the audit of our year-end financial statements, reviews of our condensed financial statements and services that are normally provided by our independent registered public accounting firm in connection with statutory and regulatory filings. |
(2) | Audit-Related Fees. Audit-related fees consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of our year-end financial statements and are not reported under “Audit Fees.” These services include attest services that are not required by statute or regulation and consultation concerning financial accounting and reporting standards, including permitted due diligence services related to a potential business combination. |
(3) | Tax Fees. Tax fees consist of fees billed for professional services relating to a tax consulting project. |
(4) | All Other Fees. All other fees consist of fees billed for all other services. |
(a) | The following documents are filed as part of this Annual Report on Form 10-K: |
(b) | Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K. |
* | Previously filed and incorporated herein by reference. |
† | Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request. |
‡ | This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act. |
QT Imaging Holdings, Inc. | ||||||
Date: March 22, 2024 | By: | /s/ Dr. Raluca Dinu | ||||
Dr. Raluca Dinu | ||||||
Chief Executive Officer |
Name |
Title |
Date | ||
/s/ Dr. Raluca Dinu |
Chief Executive Officer (Principal Executive Officer) |
March 22, 2024 | ||
Dr. Raluca Dinu | ||||
/s/ Anastas Budagov |
Chief Financial Officer (Principal Financial and Accounting Officer) |
March 22, 2024 | ||
Anastas Budagov | ||||
/s/ Dr. Avi S. Katz |
Chairman of the Board of Directors | March 22, 2024 | ||
Dr. Avi S. Katz | ||||
/s/ Dr. John Klock |
Director | March 22, 2024 | ||
Dr. John Klock | ||||
/s/ Daniel Dickson |
Director | March 22, 2024 | ||
Daniel Dickson | ||||
/s/ Zeev Weiner |
Director | March 22, 2024 | ||
Zeev Weiner | ||||
/s/ James Greene |
Director | March 22, 2024 | ||
James Greene | ||||
/s/ Ross Taylor |
Director | March 22, 2024 | ||
Ross Taylor |
Exhibit 14
CORPORATE POLICY: Code of Business Conduct and Ethics
Policy Name: | Code of Business Conduct and Ethics | |
Version: | 1.0 | |
Effective Date: | March 12, 2024 | |
Classification: | Public |
I. INTRODUCTION
A. Purpose
The purpose of this QT Imaging Holdings Code of Business Conduct and Ethics (the Code) is to confirm the commitment of QT Imaging Holdings, Inc. (the Company) and its subsidiaries to conduct its business in strict compliance with all applicable laws and regulations, so too it expects its employees, officers, and directors to act in accordance with the highest standards of business ethics both on and off Company premises, and to avoid any appearance of impropriety. The Company greatly depends upon its employees, officers, and directors for their adherence to sound business principles, compliance with applicable laws, rules and regulations, and dedication to high ethical business standards. With this Code, we, as employees, officers and directors, share in the responsibility of developing and maintaining the honesty and integrity of our Company.
This Code is intended as one element in the Companys efforts to ensure lawful and ethical conduct on the part of you and the Company. It includes general principles. You will have to apply these principles to your own specific responsibilities. This Code is part of a more extensive process that includes compliance with the Companys policies, an open relationship between you and your supervisors that is conducive to good business conduct and, above all, your integrity and good judgment.
In that regard, you must:
| comply with applicable laws, rules, and regulations; |
| conduct all dealings with the Companys customers, suppliers, and competitors fairly, with honesty, and with integrity; |
| ethically manage conflicts of interest, both real and perceived, in personal and professional relationships; |
| produce, or cause to be produced, full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with or submits to the Securities and Exchange Commission (the SEC) and in other public communications. |
| protect information, in any form, which belongs to the Company, its customers, and suppliers; |
| protect the Companys assets and ensure their efficient use and report any suspected incident of fraud or theft immediately; |
| never use your position with the Company or Company assets or information for improper personal gain. |
The policies encompassed by this Code apply everywhere where the Company conducts business. Certain foreign and U.S. federal and state laws and regulations, and the rules governing transactions with foreign, federal, state, and municipal agencies, may apply to particular aspects of the Companys business. Some of these laws are straightforward, but others may be relatively complex. In addition, the regulation of international business is quite complex, and international business practices and ethics may differ from those in the United States. This Code governs all of the Companys affairs in the United States and abroad.
You are expected to abide by the spirit as well as the letter of this Code. You are also expected to cooperate with any inquiries or investigations concerning a possible or suspected violation of this Code.
You must report potential or actual violations of this Code using the procedures discussed below. Under no circumstances will you be subject to any disciplinary or retaliatory action for reporting a violation or potential violation, or for participating in any related investigation unless it is determined that you violated this Code. However, knowingly making false or malicious reports will not be tolerated and you will be subject to appropriate disciplinary action if you file such reports.
B. Important Information
You are encouraged to read this Code carefully. As an employee, officer or director of the Company, it is your responsibility to be familiar with this Code. However, no representation is expressed or implied that the policies stated in this Code are all of the Companys relevant policies, or that they are a comprehensive, full, or complete explanation of the laws or standards of conduct that are applicable to you or the Company. You have a continuing obligation to familiarize yourself with applicable law and Company policy.
Any failure to follow the guidelines outlined in this Code could lead to your being disciplined, discharged, or removed, as the case may be, by the Company and/or possible exposure to civil and criminal penalties under federal and state laws. In addition, as a result of improper conduct, the Company may be subjected to prosecution and significant penalties.
Page 2 of 15
It is important to remember that this Code is not a contract of employment and does not create any contractual rights of any kind between the Company and its employees, officers, and directors. In addition, the Company reserves the exclusive right to modify or change this Code and its contents at any time without prior notice.
You must sign a certification in the attached form acknowledging receipt of this Code. This Code is available on the Companys intranet. This Code is also available to the public on the Companys website at [www.qtimaging.com/ ].
II. WHO TO CONTACT
If you have any questions about this Code or any concerns as to whether certain conduct may be wrong, illegal, or unethical, or if a situation is difficult or confusing to you, you are encouraged to discontinue any action and immediately request assistance by contacting your manager or the person named below:
Board Representative, Ross Taylor
Email: [email protected]
III. LAWFUL AND ETHICAL BEHAVIOR
The foundation on which this Code of Business Conduct and Ethics is built is obeying the law and acting ethically. It is the Companys policy that you conduct business in accordance with applicable federal, state, and local laws, rules, and regulations and with the laws, rules, and regulations of other countries in which the Company does business. In addition, the Companys policy demands that you adhere to the highest standard of business ethics and conduct.
You must be alert and sensitive to situations that could result in illegal, unethical, or improper action. When you are faced with a business decision that seems to have ethical overtones, here are some questions that should be helpful to determine if your actions are proper:
| Do I have all the necessary facts? |
| Am I informed about all of the legal implications? |
| Who has an important stake in the outcome (e.g., employees, customers, suppliers, etc..), and what is that stake? |
| Does the issue raise ethical issues that go deeper than legal or institutional concerns? |
Page 3 of 15
| What are the options for acting, and which options will produce the most good and do the least harm? |
| Which options respect the dignity of all stakeholders? |
| Would I be proud to explain my actions to my family, fellow employees, customers - or on tonights news broadcast? |
If you remain uncertain about what to do, if you need advice, or if you have reason to believe that a U.S. or foreign law could be violated in connection with Company business or that this Code has been violated in any way, notify your manager, an executive officer, or the above-named Board Representative at once.
IV. ETHICAL STANDARDS
This Code contains standards reasonably necessary to promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the issuer and in other public communications; and compliance with applicable laws, rules and regulations.
You must:
(a) | Act with honesty and integrity, avoiding actual or apparent conflicts of interest in personal and professional relationships. You should recognize that even the appearance of a conflict of interest can damage the Company. A conflict of interest may exist because of a relationship of an employee or of a family member that is inconsistent with the Companys best interests or could cause a conflict with the employees ability to perform his or her job responsibilities. |
(b) | Promptly report to your manager, an executive officer, or the above-named Board Representative any transaction that reasonably could be expected to give rise to a conflict of interest. |
(c) | Produce, or cause to be produced, full, fair, accurate, timely and understandable |
(d) | disclosure in reports and documents that the Company files with or submits to the SEC and in other public communications. |
(e) | Comply with applicable laws, rules, and regulations. |
(f) | Promptly report any violation of this Code to your manager, an executive officer, or the above-named Board Representative. |
(g) | Proactively promote ethical behavior by other Company officers and employees involved in financial reporting. |
Page 4 of 15
If you are a senior executive officer (chief executive officer, chief financial officer, principal financial officer or controller), other executive officer or director, any request by you for a waiver of
the requirements in any of the above provisions of these Ethical Standards must be in writing and addressed to the Chairperson of the Audit Committee. If you are not an executive officer or director, any request by you for a waiver of the requirements in any of these provisions must be in writing and addressed to an executive officer or the above-named Board Representative.
With regard to senior financial officers, other executive officers and directors, the Board will have the sole and absolute discretionary authority, acting upon such recommendation as may be made by the Audit Committee, to approve any requested waiver of the requirements in any of the above provisions of these Ethical Standards. Any such approved waiver for senior financial officers, other executive officers or directors will be disclosed promptly on Form 8-K or any other means that complies with SEC rules or applicable listing standards.
V. CONFLICTS OF INTEREST
The Company knows that it can only be truly successful through the diligence and loyalty of its employees, officers, and directors. Therefore, you must put the best interests of the Company at the forefront of any work-related activity or decision and ethically manage conflicts of interest. You must use your best judgment in determining whether a conflict of interest exits and then avoid any conduct, activity, relationship, or other situation that would create an actual or potential conflict of interest or create the appearance of such a conflict.
While it is not possible to identify every particular activity that might give rise to a conflict of interest, conflicts of interest may arise, for example, when an employee engages in a personal activity or has a personal interest that depends upon a specific outcome in the business of the Company. These personal activities or interests may influence the employees judgment, causing the employee to make decisions based upon the potential for personal gain, rather than in the best interests of the Company.
If you or your family members are engaged in any of the activities listed below, then there may be a conflict of interest, and you must disclose the facts concerning this activity to your manager, an executive officer, or the above-named Board Representative in order to have the Company address the situation:
(a) | any ownership interest in any supplier, customer, or competitor (other than nominal amounts of stock in publicly traded companies); |
(b) | any consulting or employment relationship with any customer, supplier, or competitor; |
Page 5 of 15
(c) | any outside activity that harms a relationship between the Company and any customer or potential customer, or that interferes with a current or potential contract relationship; |
(d) | any outside business activity that is competitive with any of the Companys businesses or subsidiaries; |
(e) | any outside activity of any type that is so substantial as to call into question your ability to devote appropriate time and attention to your duties and responsibilities to the Company; |
(f) | any service on any board of directors or advisory board of any customer, supplier, or competitor unless such board service has been disclosed to the Company; |
(g) | any sales or purchases of anything to or from the Company (unless it is pursuant to a routine program of disposal of surplus property that is offered to all employees in general); and |
(h) | any situation in which, without proper authorization, you are required or tempted to disclose, or do disclose, any trade secret, confidential or proprietary information or intellectual property of the Company. |
The list above serves only to illustrate sources of possible conflicts of interest and does not constitute a complete list of all the situations that may result in a conflict of interest. Ultimately, it is the responsibility of each employee to avoid any situation that could affect his/her ability to judge situations independently and objectively or even appear to be a conflict of interest. It is important to note that under certain circumstances, conflicts of interest can amount to violations of criminal law. If you have any questions regarding activity which may create a conflict of interest, please discuss the situation immediately with your manager, an executive officer, or the above-named Board Representative. If you know of a conflict of interest that exists elsewhere in the Company, you must disclose such conflict to your manager, an executive officer, or the above-named Board Representative.
The Company reserves the right to determine when actual or potential conflicts of interest exist, and then to take any action, which in the sole business judgment of the Company, is needed to prevent the conflict from continuing.
Such action may include, but is not limited to, having you divest the conflicting interest or return the benefit or gain received, realigning your duties and responsibilities, or disciplinary action, up to and including immediate termination of your employment.
Gifts and Entertainment
Generally, you and your family members may not accept gifts, services, discounts, or favors from those with whom the Company does business or considers doing business. Gifts, entertainment, favors, or gratuities are subject to the following guidelines:
(a) You may accept gifts of nominal value ordinarily used for sales promotion (for example, calendars, appointment books, pens, etc.,).
Page 6 of 15
(b) Ordinary business lunches or reasonable entertainment consistent with local social and business customs may also be permissible if these actions can be reciprocated by you and are reasonable in cost and frequency.
If you receive a gift that does not fall within these guidelines, you must report it to your manager and return the gift. If the return of the gift is not practical, you should give it to the Company for charitable disposition or such other disposition as the Company deems appropriate.
Employment of Relatives and Significant Others
Supervisory relationships with family members present special workplace problems, including the potential for an appearance of a conflict of interest, in various personnel decisions that the supervisor makes. Accordingly, although not prohibited, Company employees should avoid a direct reporting relationship with any member of their family or others with whom they have a personal/extraprofessional relationship. If such a relationship exists or occurs, the employees must report it in writing to human resources.
Family members refers to a spouse or domestic partner, parents, legal guardians, siblings, children (natural, step- or adopted), grandparents, grandchildren, or current in-laws.
(Natural, step or adopted relationships are included in this definition.) This Code also applies to significant others and dating relationships.
VI. CONFIDENTIALITY
You owe a duty to safeguard confidential information of the Company from the public. Confidential information, which can be written, spoken or electronic, includes, but is not limited to, any non-public information regarding the Companys financial information, business plans, marketing strategies, product launches, pricing policies, supplier and customer lists, and other similar operational information. The
Companys confidential information may also include the Companys intellectual property, including, but not limited to, copyrights, patents, trade secrets, logos and information on the Companys products, equipment, manufacturing process, software development and research and development.
You must follow all applicable agreements and policies regarding confidentiality between you and the Company during and after your employment. You should be discreet with respect to confidential information in public and not communicate confidential information to any person unless that person has a legitimate, Company-related reason to access that information. Neither should you use any confidential information other than for legitimate, Company-related purposes. You should also ensure that a non-disclosure agreement is in effect and is approved by management before providing or receiving any confidential information from a third party.
Page 7 of 15
VII. CORPORATE OPPORTUNITIES
You may not use corporate property, information, or position for improper personal gain. You owe a duty to the Company to advance its legitimate interests when the opportunity to do so arises. You are prohibited from competing with the Company or taking advantage for personal gain of any opportunity that is discovered through the use of Company property, information or position. You should report any corporate opportunity to your manager or other appropriate individual within the Company to determine whether the Company desires to take advantage of the opportunity.
If you are an officer, you have an additional obligation not to take advantage for personal gain of any opportunity that the Company may have an interest in pursuing, notwithstanding that your knowledge of such opportunity is obtained independently of your relationship with the Company.
VIII. FAIR DEALING
The Company seeks to compete fairly through innovation and superior performance, and it prohibits any unethical or illegal business practices, including, without limitation, corruption, bribery, kickbacks, extortion, and embezzlement. Furthermore, you should endeavor to deal fairly with the Companys customers, suppliers, competitors, and employees. No director, officer or other employee should take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other practice involving unfair dealing.
IX. ACCOUNTING AND FINANCIAL INTEGRITY, FRAUD, AND IMPROPER PAYMENTS
As noted in the Ethical Standards set forth above, the Company requires full, fair, accurate, timely and understandable recording and reporting of all Company information. The Companys books, records and accounts must reflect, accurately and fairly, and within the Companys normal system of accounting, all of its transactions. Therefore, you must act in a manner that ensures that all of the Companys books, records, accounts, and financial statements are maintained in reasonable detail, appropriately reflect the Companys transactions, and conform both to applicable legal requirements and to the Companys system of internal controls.
Good financial reporting starts with good recordkeeping, and the Company and its management rely on its records to prepare financial statements that present its results of operations and financial position in a full, fair, accurate, timely and understandable manner. These financial statements are relied on by stockholders, creditors, governmental authorities, and the public. It is, therefore, critical that all employees involved with recording, summarizing, and maintaining business and accounting records do so in accordance with the following:
Page 8 of 15
| All assets, liabilities, revenues, and expenses will be recorded in the financial records of the Company and its subsidiaries; |
| No undisclosed or unrecorded funds or accounts will be established for any purpose; |
| No false or artificial entries will be made for any reason; and |
| No payments will be approved or made with the intention or understanding that any part of the payments is to be used for any purpose other than that described by the documentation supporting the payment. |
In addition, everyone must execute and record transactions in accordance with all internal control procedures implemented by Company management. Furthermore, all of your expense reimbursements must accurately reflect the true nature and amount of the expenses.
It is especially important that you do not create, or participate in the creation, or perpetuation of, any records that are intended to mislead anyone or conceal any improper act of conduct.
Furthermore, if you are in any way involved in preparing the Companys disclosure documents (such as SEC filings or press releases), you must produce full, fair, accurate, timely, and understandable disclosure in such documents.
Persons involved in preparing and finalizing the Companys financial information, whether for internal or external reporting purposes, and disclosure documents should do so in accordance with the following:
| Assist in maintaining internal control over financial reporting. |
| Inform the Chief Accounting Officer or the above-named Board Representative or such other individuals responsible for ensuring that appropriate controls and procedures are in place and followed for all quarterly and annual financial filings promptly of business transactions, events or circumstances that could have a material impact on the Companys financial statements. |
| Communicate openly and honestly with the Companys external public accountants with respect to quarterly and annual financial reporting and related disclosures. |
| Ensure the financial statements and related disclosures include all information deemed necessary to achieve an appropriate degree of transparency of business transactions. |
Reporting Your Concerns
To facilitate the reporting of colleague concerns, the Company has established the following procedures for the confidential and/or anonymous submission by employees of concerns regarding accounting, internal accounting controls, or auditing matters (Accounting Matters).
Page 9 of 15
Colleagues with concerns regarding Accounting Matters must report such concerns by contacting the Chief Accounting Officer or the above-named Board Representative, which may be done on a confidential basis.
Reports to the Chief Accounting Officer or the above-named Board Representative may be made in writing or orally, although the person who is reporting any such matters is advised to follow up in writing to ensure there is a written record of report; provided, however, the report may be submitted anonymously. The Chief Accounting Officer or the above-named Board Representative will initially review reports and those involving Accounting Matters will be reported by this member of the Board to the Chairman of our Audit Committee. All such reports will be investigated under Audit Committee direction and oversight by the above-named Board Representative, director of internal audit or other person as our Audit Committee may determine. Prompt and appropriate corrective action will be taken when and as warranted in the judgment of the Audit Committee. If the reported concern was not made on an anonymous basis, the Chief Accounting Officer or the above-named Board Representative will respond to the person making the report after the investigation is completed.
Non-Retaliation
While complaints and concerns regarding Accounting Matters may be made on an anonymous basis, you are encouraged to identify yourself so that the Company can contact you in the event further information is needed or to report our response to your concern. You should always be expected to participate in any investigation into a report made by you so that you can answer questions that may be relevant to the
Companys investigation into such report. In any case, your identity in making a report, or otherwise participating in a follow-on investigation concerning the same, will be maintained in confidence to the fullest extent possible, consistent with the need to conduct an adequate review. Retaliation against those who bring forward these types of related concerns or complaints will not be tolerated. The Company will not discharge, demote, suspend, threaten, harass or in any manner discriminate against any employee in the terms and conditions of employment based upon any lawful actions of such employee with respect to good faith reporting of concerns regarding Accounting Matters or otherwise as specified in Section 806 of the Sarbanes-Oxley Act of 2002.
If an employee, applicant, or vendor believes that he or she has been retaliated against for disclosing information regarding misconduct under the Code, he/she should file a written complaint with the above- named Board Representative.
Fraud
Company policy prohibits all fraudulent activity. Fraud includes, but is not limited to, the following actions:
| dishonest or fraudulent acts; |
Page 10 of 15
| embezzlement of Company funds; |
| forgery or alteration of negotiable instruments such as Company checks and drafts; |
| misappropriation of Company, employee, customer, partner, or suppliers property, including, but not limited to, trade secrets or other confidential information that may be proprietary to the Company, but not rise to the level of a trade secret; |
| conversion to personal use of cash, securities, supplies or any other Company assets; |
| unauthorized handling or reporting of Company transactions; |
| falsification or material omission of client or prospective client records or information for any reason; and |
| falsification of Company records or financial statements for personal or other reasons. |
Any violations of the Companys fraud policy will result in immediate dismissal. Any employee, officer, director, or agent who suspects that any fraudulent activity has occurred, or may potentially occur, is required to report such concern to their manager, an executive officer, or the above-named Board Representative immediately.
Improper Payments
The Company observes the highest ethical standards in all of its business transactions including those involving foreign countries. You may not take any action in connection with any international transaction or action in any foreign country that would be illegal or improper in the United States. Furthermore, you are required to observe all applicable foreign laws to which you or the Company may be subject, including foreign laws, customs duties and regulations and currency restrictions. Under no circumstances is it acceptable to offer, give, solicit, receive, or authorize any form of bribe, kickback, or improper inducement, payment, or gift in connection with Company business. This principle applies to Company transactions everywhere in the world, even in situations where the practice is widely considered a way of doing business. Under federal statutes (such as the U.S. Foreign Corrupt Practices Act), these are criminal acts that can lead to prosecution. If you are asked to make any such payment, you should consult with your manager, an executive officer, or the above-named Board Representative before taking any action.
In order to ensure that you are acting on the Companys behalf and are not offering or receiving what could be considered to be a bribe, kickback, or other fraudulent activity, you must periodically undergo specialized training on the U.S. Foreign Corrupt Practices Act and other applicable laws and regulations about business gifts, and direct questions to the Legal Department. Limits on authority must be strictly observed and payments above authorized levels require advance approval by your manager in conjunction with the Finance Department.
Page 11 of 15
X. POLITICAL ACTIVITIES AND COMPLIANCE WITH CAMPAIGN FINANCE LAWS
The Company encourages its directors, officers, and employees to be active members of their communities. Along with participation in civic, charitable, and volunteer activities, this includes participation in the political process and may involve monetary contributions to political candidates and causes.
It is the Companys policy not to make any political contributions in connection with any federal, state, and local elections in violation of campaign finance laws. You may not make a political contribution on the Companys behalf or cause the Company to be directly or indirectly liable for any political contributions without pre-approval. The Companys resources may not be used to support the cost of fund-raising events, including the cost of food and beverage. You shall not include any political contributions or cost of a fundraising event on your expense accounts or in any other way that would result in reimbursement by the Company.
XI. PUBLIC STATEMENTS
All public statements about or on behalf of the Company must be carefully coordinated and approved in advance by the Company. Unless he or she has been authorized to do so, no employee should make public statements about or on behalf of the Company. If you receive a request for information or an interview about the Company, you should politely decline and direct the request to an executive officer or the above-named Board Representative.
XII. SOCIAL MEDIA
At QT Imaging Holdings, you should be discreet with respect to sharing ideas through Internet, including social networking sites, blogs, wikis, music or audio-sharing, media platforms and virtual worlds. You should not post any confidential information about the Company. You should not inappropriately discuss anything about the Company, colleagues, customers, business partners, and other stakeholders. On social media, unless you are specifically authorized to do so, you must not give the impression that you are acting on the Companys behalf. If you believe you have witnessed improper activities on social media, please promptly notify your manager, an executive officer or the above-named the Board Representative.
XIII. TEAM MEMBER PRIVACY
Your colleagues have a right to privacy to confidential information about themselves that they have provided to you and the Company in the course of their work. Their information may include their employment history, government-issued identification numbers, personal contact information, marital status, and medical history. You have a responsibility to protect their privacy by taking appropriate precautions to safeguard their information and using it only pursuant to your job. For questions about the privacy laws in the workplace, seek advice from your manager, an executive officer, or the above-named Board Representative.
Page 12 of 15
XIV. HEALTH AND SAFETY
The Company recognizes that a safe and healthy workplace is essential to all aspects of business and innovation. All employees should maintain a safe and healthy workplace by following the Companys safety and health rules and practices and reporting accidents, injuries, and unsafe equipment, practices, or conditions.
XV. SEXUAL HARASSMENT
The Company prohibits all types of sexual harassment that may include inappropriate sexual remarks or jokes, sexually suggestive comments, inappropriate comments about someones appearance, visual displays such as sexually oriented gestures or derogatory pictures, unwanted sexual advances, invitations, touching, requests for sexual favors and threats to submit to sexual demands. If you feel that you have observed or experienced any of the above, please report the issue to your manager, an executive officer, or the above-named Board Representative.
XVI. IMPLEMENTATION OF THE CODE
Acknowledgment of the Code
As a condition of employment, officership and directorship of the Company, or continuation of such, as the case may be, all employees, officers and directors will be asked to review the Code of Business Conduct and Ethics and sign an Acknowledgement, which Acknowledgement shall state the following (or include language similar thereto):
I have received and read the QT Imaging Holdings Code of Business Conduct and Ethics and agree to comply with its policies and requirements. I understand that the Code represents the current policies of QT Imaging Holdings and that they may be modified at any time without prior notice. I have complied with all of the requirements of this Code, and neither I to date failed to meet any requirements contained therein, nor do I know of failures by others within the Company to meet the requirements. I will carry out my responsibilities in compliance with the Code.
You should retain a copy of any Acknowledgement that you sign for your own files. The Company will also retain records or copies of such documentation.
Page 13 of 15
Compliance with the Code
Except as delegated by the Board of Directors to the Compliance Committee, the Board of Directors has retained the ultimate responsibility for overseeing compliance with all applicable laws, governmental regulations and policies, the Code and all other related Company policies and procedures and has appointed the above-named Board Representative to serve as the point person for communicating with the Board of Directors with regard to such compliance matters.
It is the responsibility of all employees, officers, and directors to comply with all applicable laws, regulations, governmental policies, the Code and the Companys related policies and procedures. It is the responsibility of all Company supervisory personnel to monitor compliance with this Code. The Board of Directors will periodically review for compliance with the Companys policies and procedures. In some cases, the Company will monitor compliance with the Code and the Companys policies by audits, or otherwise ask you to certify that you are not aware of any violations of the Code. Any audit may be done at the direction of the Board of Directors, using Company personnel or legal counsel. You are required to cooperate fully with any such certification requests or audits and to provide truthful and accurate responses to any request.
Reporting Violations
In the event you believe that you have observed or have participated in any conduct or practices that you believe are unethical, inappropriate, or improper, you must immediately report the matter to your manager, an executive officer, or the above-named Board Representative. If you are involved in a violation of the Code, you must also report it immediately to your manager, an executive officer, or the above-named Board Representative. The fact that you reported the violation, together with the degree of cooperation displayed by you and whether the violation was willful or unintentional, will be given consideration by the Company in any resulting disciplinary action. Except as provided in the next paragraph, it is required that you give your identity when reporting suspected violations to allow the Company to contact you in the event further information is needed to pursue, or in connection with, an investigation. Reports of suspected violations of the Code must be in writing. A sufficiently detailed description of the factual basis for the report should be given in order to allow an appropriate investigation. Reports may be emailed to the above-named Board Representative at [email protected]; or by mail at: Attention: Ross Taylor, Director, 1731 Embarcadero Rd., Suite 200, Palo Alto, CA 94303.
Violations or concerns relating to accounting or auditing matters should be reported using the procedures set forth under the heading Accounting and Financial Integrity, Fraud and Improper Payments. Your identity will be maintained in confidence to the fullest extent practicable under the circumstances and in accordance with the Companys legal obligations.
No person reporting a violation or suspected violation will be made to suffer public embarrassment or be subject to harassment or retaliation because of any good faith reporting. Any employee, officer or director of the Company who attempts or is responsible for reprisals against individuals, who in good faith report known or suspected violations, will be subject to disciplinary action. However, the submission of reports that are known to be false constitutes a violation of the Code and will result in stern disciplinary action.
Page 14 of 15
Investigations of Violations
All investigations will be coordinated by the Board Representative or the Audit Committee and, as necessary, with the Companys legal counsel. Employees, officers, and directors are expected to fully cooperate in the investigation of any alleged violation of the Code or related Company policies or procedures. If the result of an investigation indicates that corrective action is required, the Company will decide what steps it should take to rectify the problem and avoid its recurrence. It is imperative that reporting employees, officers or directors do not conduct their own preliminary investigations.
Investigations of an alleged violation may involve complex legal issues. Acting on your own may compromise the integrity of an investigation and adversely affect both you and the Company. You should always be expected to participate in any investigation into a report made by you so that you can answer questions that may be relevant to the Companys investigation into an alleged violation of the Code.
Availability of the Code
All employees, officers and directors of the Company will receive a personal copy of this Code. If at any time you need an additional copy of the Code, please contact your manager, and that person will promptly provide you with another copy. In addition, a copy of this Code is available on the Companys intranet and external websites, located at [www.qtimaging.com/ ].
Page 15 of 15
Exhibit 21.1
SUBSIDIARIES
QTI MERGER SUB, INC.
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Raluca Dinu, certify that:
1. | I have reviewed this Annual Report on Form 10-K of QT Imaging Holdings, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;; |
(c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: March 22, 2024 | By: | /s/ Dr. Raluca Dinu | ||||
Name: Dr. Raluca Dinu | ||||||
Chief Executive Officer |
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Anastas Budagov, certify that:
1. | I have reviewed this Annual Report on Form 10-K of QT Imaging Holdings, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;; |
(c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: March 22, 2024 | By: | /s/ Anastas Budagov | ||||
Name: Anastas Budagov | ||||||
Chief Financial Officer |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of QT Imaging Holdings, Inc. (the Registrant) on Form 10-K for the period ending December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
Date: March 22, 2024 | By: | /s/ Dr. Raluca Dinu | ||||
Name: Dr. Raluca Dinu | ||||||
Chief Executive Officer |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of QT Imaging Holdings, Inc., (the Registrant) on Form 10-K for the period ending December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the Report), I certify, in the capacity and on the date indicated below, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. |
Date: March 22, 2024 | By: | /s/ Anastas Budagov | ||||
Name: Anastas Budagov | ||||||
Chief Financial Officer |
Exhibit 97.1
QT IMAGING HOLDINGS, INC.
POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION
(Adopted as of January 11, 2024)
1. | INTRODUCTION |
The Board of Directors (the Board) of QT Imaging Holdings, Inc. (the Company) is adopting this policy (this Policy) to provide for the Companys recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circumstances. This Policy is effective as of December 1, 2023 (the Effective Date).
This Policy is administered by the Board. The Board shall have full and final authority to make any and all determinations required or permitted under this Policy. Any determination by the Board with respect to this Policy shall be final, conclusive and binding on all parties. The Board may amend or terminate this Policy at any time.
This Policy is intended to comply with Section 10D of the Securities and Exchange Act of 1934, as amended (the Exchange Act), Rule 10D-1 thereunder and the applicable rules of any national securities exchange on which the Companys securities are then listed (the Exchange) and will be interpreted and administered consistent with that intent.
Each Affected Officer subject to this Policy must execute the Acknowledgment and Agreement attached hereto as Exhibit A before such Affected Officer will be entitled to receive any cash- or equity-based incentive compensation that is approved, granted or awarded on or after the Effective Date.
2. | EFFECTIVE DATE |
This Policy shall apply to all Incentive Compensation received by an Affected Officer on or after October 2, 2023 to the extent permitted or required by applicable law or the rules of the Exchange.
3. | DEFINITIONS |
For purposes of this Policy, the following terms shall have the meanings set forth below:
Affected Officer means any current or former officer as defined in Exchange Act Rule 16a-1.
Erroneously Awarded Compensation means the amount of Incentive Compensation received within the three completed fiscal years immediately preceding the date on which the Company was required to prepare the Restatement (including any transition period within or immediately following those years that results from a change in the Companys fiscal year, provided that a transition period of nine to 12 months will be deemed to be a completed fiscal year) (the look-back period) that exceeds the amount of Incentive Compensation that otherwise would have been received had it been determined based on the Restatement, computed without regard to any taxes paid. In the case of Incentive Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the Restatement, the amount shall reflect a reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive Compensation was received, as determined by the Board in its sole discretion. The Board may determine the form and amount of Erroneously Awarded Compensation in its sole discretion.
Financial Reporting Measure means any measure that is determined and presented in accordance with the accounting principles used in preparing the Companys financial statements, and any measures that are derived wholly or in part from such measures, whether or not such measure is presented within the financial statements or included in a filing with the Securities and Exchange Commission. Stock price and total shareholder return are also Financial Reporting Measures.
Incentive Compensation means any compensation that is granted, earned or vested based in whole or in part on the attainment of a Financial Reporting Measure. For purposes of clarity, base salaries, bonuses or equity awards paid solely upon satisfying one or more subjective standards, strategic or operational measures, or continued employment are not considered Incentive Compensation, unless such awards were granted, earned or vested based in part on a Financial Reporting Measure.
Restatement means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (i.e., a Big R restatement), or that would result in a material misstatement if the error was corrected in the current period or left uncorrected in the current period (i.e., a little r restatement).
4. | RECOVERY |
If for a fiscal period ending on or after October 2, 2023, the Company is required to prepare a Restatement, the Company shall seek to recover reasonably promptly all Erroneously Awarded Compensation that results from attainment of a Financial Reporting Measure based on or derived from financial information for any fiscal period ending on or after October 2, 2023 and that is received by an Affected Officer after such Affected Officer begins service as an Affected Officer, provided that such Affected Officer served as an Affected Officer during the performance period for that Incentive Compensation and while the Company has a class of securities listed on the Exchange, and for such period as such Affective Officer has served as an Affected Officer during the look-back period.
For purposes of this Policy:
| Erroneously Awarded Compensation is deemed to be received in the Companys fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period; and |
| the date the Company is required to prepare a Restatement is the earlier of (x) the date the Board or any officer of the Company authorized to take such action concludes, or reasonably should have concluded, that the Company is required to prepare the Restatement, or (y) the date a court, regulator, or other legally authorized body directs the Company to prepare the Restatement. |
To the extent required by applicable law or the rules of the Exchange, any profits realized from the sale of securities of the Company are subject to recoupment under this Policy.
For purposes of clarity, in no event shall the Company be required to award any Affected Officers an additional payment or other compensation if the Restatement would have resulted in the grant, payment or vesting of Incentive Compensation that is greater than the Incentive Compensation actually received by the Affected Officer. The recovery of Erroneously Awarded Compensation is not dependent on if or when the Restatement is filed.
5. | SOURCES OF RECOUPMENT |
To the extent permitted by applicable law, the Board may, in its discretion, seek recoupment from the Affected Officer(s) through any means it determines, which may include any of the following sources: (i) prior Incentive Compensation payments; (ii) future payments of Incentive Compensation; (iii) cancellation of outstanding Incentive Compensation; (iv) direct repayment; and (v) non-Incentive Compensation or securities held by the Affected Officer. To the extent permitted by applicable law, the Company may offset such amount against any compensation or other amounts owed by the Company to the Affected Officer.
2
6. | LIMITED EXCEPTIONS TO RECOVERY |
Notwithstanding the foregoing, the Board, in its discretion, may choose to forgo recovery of Erroneously Awarded Compensation under the following circumstances, provided that a majority of the independent members of the Board has made a determination that recovery would be impracticable because:
(i) | The direct expense paid to a third party to assist in enforcing this Policy would exceed the recoverable amounts; provided that the Company has made a reasonable attempt to recover such Erroneously Awarded Compensation, has documented such attempt and has (to the extent required) provided that documentation to the Exchange; |
(ii) | Recovery would violate home country law where the law was adopted prior to November 28, 2022, and the Company provides an opinion of home country counsel to that effect to the Exchange that is acceptable to the Exchange; or |
(iii) | Recovery would likely cause an otherwise tax-qualified retirement plan to fail to meet the requirements of the Internal Revenue Code of 1986, as amended. |
7. | NO INDEMNIFICATION OR INSURANCE |
The Company will not indemnify, insure or otherwise reimburse any Affected Officer against the recovery of Erroneously Awarded Compensation.
8. | NO IMPAIRMENT OF OTHER REMEDIES |
This Policy does not preclude the Company from taking any other action to enforce an Affected Officers obligations to the Company, including termination of employment, institution of civil proceedings, or reporting of any misconduct to appropriate government authorities. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 that are applicable to the Companys Chief Executive Officer and Chief Financial Officer.
3
QT IMAGING HOLDINGS, INC.
POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION
ATTESTATION AND ACKNOWLEDGEMENT
By my signature below, I acknowledge and agree that:
| I have received and read the attached Policy for Recovery of Erroneously Awarded Incentive Compensation (as it may be amended, restated, supplemented or otherwise modified from time to time, the Policy) of QT Imaging Holdings, Inc. (the Company). Any capitalized terms used and not defined in this Attestation and Acknowledgement shall have the meaning set forth in the Policy. |
| I am fully bound by, and subject to, all of the terms and conditions of the Policy. In the event of any inconsistency between the Policy and the terms of any employment agreement to which I am a party, or the terms of any compensation plan, program or agreement under which any compensation has been granted, awarded, earned or paid, the terms of the Policy shall govern. |
| In the event it is determined by the Board of Directors of the Company that any amounts granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company, I hereby agree to abide by all of the terms of this Policy both during and after my employment with the Company, including, without limitation, by promptly repaying or returning any Erroneously Awarded Compensation to the Company as determined in accordance with this Policy. |
Date:
Agreed and Acknowledged
[Name of Affected Officer]
Exhibit 99.1
QT IMAGING HOLDINGS, INC.
AUDIT COMMITTEE CHARTER
Mission Statement
The Audit Committee (the Committee) of QT Imaging Holdings, Inc. (the Company) is appointed by the Board of Directors as a permanent committee to assist it in monitoring and overseeing (1) the accounting and financial reporting processes of the Company and the audits of the financial statements of the Company, (2) the preparation and integrity of the financial statements of the Company, (3) the compliance by the Company with financial statement and regulatory requirements, (4) the performance of the Companys internal finance and accounting personnel and its independent registered public accounting firm, and (5) the qualifications and independence of the Companys independent registered public accounting firm.
In particular, and without limiting the generality of the foregoing, the purpose of the Committee is to undertake the duties of an audit committee described in, and otherwise to assist the Company in complying with the requirements of the applicable rules of the Securities and Exchange Commission (the Commission), the Financial Industry Regulatory Authority (FINRA), or of any securities exchange or trading facility to which the Company is or may become subject.
In carrying out its functions, the Committee shall serve as an independent and objective monitor of the performance of the Companys financial reporting processes and system of internal controls; review and assess the audit work of the Companys independent registered public accounting firm and internal accounting and finance personnel; and facilitate open, ongoing communication among the independent registered public accounting firm, internal financial and accounting personnel, senior management, and the Board of Directors concerning the Companys financial condition and results of operations and financial reporting practices.
Organization and Membership
Each member of the Committee shall be appointed by the Board of Directors at its annual meeting, on the recommendation of the Nominating and Corporate Governance Committee, to serve at the pleasure of the Board of Directors until the next annual meeting of shareholders or until such Members replacement has been appointed. The Board of Directors will select the chair of the Committee (the Chair).
The Committee will be comprised of not less than three members of the Board of Directors (the Members), each of whom shall qualify as an independent director pursuant to the independence requirements of the Sarbanes-Oxley Act of 2002 and as provided for under Rule 10A-3(b)(1) of the Exchange Act of 1934 (subject to the exemptions provided in Rule 10A-3(c)), as such requirements are interpreted by the Board of Directors in its business judgment and the Board of Directors shall annually review the Committees compliance with such requirements. The Members shall also satisfy the independence and experience requirements of The Nasdaq Stock Market LLC (Nasdaq), provided that the Committee membership shall be subject to the exemptions afforded issuers under SEC and Nasdaq rules. Specifically, there shall be a maximum of one director who does not meet the independence criteria of Nasdaq, and who is not a current employee or officer, or an immediate family member of an employee or officer, may be appointed to the Committee, subject to the approval of the Board pursuant to, and subject to the limitations under, the exceptional and limited circumstances exceptions as provided under the rules of Nasdaq. In addition, the Committee shall not include any member who:
| is a former partner or director of the Companys existing auditing firm (i) if such position has been held within the prior 12 months, or (ii) if such person has any financial interest in the auditing firm; |
| has participated in the preparation of the financial statements of the Company or any current subsidiary at any time during the past three (3) years; |
| accepts any consulting, advisory or other compensatory fee, directly or indirectly, from the Company, other than in his or her capacity as a member of the Committee, the Board or any other committee of the Board; or |
| is an affiliate of the Company or any subsidiary of the Company, other than a director who meets the independence requirements of Nasdaq. |
Each Member must not have participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years. Each Member must be able to read and understand fundamental financial statements, including the Companys balance sheet, income statement, and cash flow statement. At least one Member must have past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience or background which results in the individuals financial sophistication, including being or having been a chief executive officer, chief financial officer or other senior officer with financial oversight responsibilities.
Meetings
In addition to meetings described in the following section, the Committee shall meet at least four times annually in conjunction with each quarterly review and annual audit of the Companys financial statements, which meetings shall be prior to the quarterly and annual earnings releases. Committee meetings may be held at such other times as the Members or the Chair may deem necessary or appropriate.
Committee meetings may be held in person or, at the option of the Chair, by conference telephone call. If any Member expects to participate in a Committee meeting by conference telephone call he or she shall so advise the Chair and, whenever reasonably possible, such Member shall be furnished with copies of financial statements, reports or other documents that will be discussed at the meeting so as to permit such Member to fully engage in the discussions as if such Member had attended the meeting in person.
Responsibilities of the Committee
The functions set forth below shall be the common recurring activities of the Committee in carrying out its oversight responsibilities. In particular, and without limiting the generality of the foregoing, the Committee shall undertake the responsibilities and duties prescribed by the regulatory body of any national securities exchange on which the Companys securities are traded, the Commission or other regulatory bodies having jurisdiction over the financial affairs of the Company. The functions set forth below shall be deemed to include such responsibilities and duties, as they may be promulgated from time to time, as if they were specifically listed below.
2
The Committees responsibility is oversight, and it recognizes that the Companys management is responsible for preparing the Companys financial statements. While the Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Committee to plan or conduct audits or to determine that the Companys financial statements are complete and accurate and are in accordance with generally accepted accounting principles or to assure compliance with laws, regulations or any internal rules or policies of the Company. The independent auditor is responsible for planning and conducting audits to determine whether the financial statements present fairly in all material respects the financial position of the Company. The Committee has direct and sole responsibility for the appointment, compensation, oversight and replacement, if necessary, of the independent registered public accounting firm, including the resolution of disagreements between management and such firm regarding financial reporting. Each Member of the Committee shall be entitled to rely on (i) the integrity of those persons and organizations within and outside the Company that it receives information from and (ii) the accuracy of the financial and other information provided to the Committee by such persons or organizations absent actual knowledge to the contrary (which shall be promptly reported to the Board of Directors). The Committee has the authority to retain legal, accounting or other experts that it determines to be necessary to carry out its duties. It also has authority to determine compensation for such advisors, as well as for the independent auditor and to determine appropriate funding needs for ordinary administrative expenses that are necessary or appropriate in carrying out the Committees duties. The Company must provide for appropriate funding, as determined by the Committee for the payment of reasonable fees to any such consultant, legal counsel or other adviser retained by the Committee.
1. Duties and Proceedings of the Audit Committee
The Committee shall assist the Board of Directors in fulfilling its oversight responsibilities by accomplishing the following:
Oversight of Independent Auditor
| Annually evaluate, determine the selection and compensation of, and if necessary, determine the replacement of or rotation of, the independent registered public accounting firm, pursuant to clear policies for audit partner rotation established by the Committee to ensure compliance with applicable laws and regulations. |
| Pre-approve all auditing services (including comfort letters and statutory audits) and all permitted non-audit services by the independent registered public accounting firm or any other registered public accounting firm engaged by the Company pursuant to pre-approval policies and procedures established by the Committee. |
| Receive formal written statements, at least annually, from the independent registered public accounting firm regarding the auditors independence, including a delineation of all relationships between the auditor and the Company; discuss with the independent registered public accounting firm any disclosed relationships or services that may impact the objectivity and independence of the independent registered public accounting firm, addressing at least the matters set forth in Independence Standards Board Standard No. 1; and if so determined by the Committee, recommend that the Board of Directors take appropriate action to satisfy itself of the independence of the registered public accounting firm. |
3
| At least annually, receive a report, orally or in writing, from the independent auditor detailing the firms internal quality control procedures and any material issues raised by the independent registered public accounting firms quality control review, peer review or any governmental or other professional inquiry performed within the past five years and any remedial actions implemented by the firm. |
Oversight of Audit Process and Companys Regulatory Compliance
| Review with each of the internal and independent registered public accounting firm the overall scope and plans for audits, including authority and organizational reporting lines and adequacy of staffing and compensation. |
| Review and discuss with management and internal auditors the Companys system of internal control and discuss with the independent registered public accounting firm any significant matters regarding internal controls over financial reporting that have come to its attention during the conduct of its audit. |
| Review and discuss with management, internal auditors and independent registered public accounting firm the Companys financial and critical accounting practices, and policies relating to risk assessment and management. |
| Receive and review reports of the independent registered public accounting firm discussing 1) all critical accounting policies and practices to be used in the firms audit of the Companys financial statements, 2) all alternative treatments of financial information within generally accepted accounting principles that have been discussed with management, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent registered public accounting firm, and 3) other material written communications between the independent registered public accounting firm and management, such as any management letter or schedule of unadjusted differences. |
| Review and discuss with management and the independent registered public accounting firm the annual and quarterly financial statements and MD&A of the Company prior to the filing of the Companys Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Discuss results of the annual audit and quarterly review and any other matters required to be communicated to the committee by the independent registered public accounting firm under generally accepted auditing standards. Discuss with management and independent registered public accounting firm their judgment about the quality of accounting principles, the reasonableness of significant judgments, including a description of any transactions as to which the management obtained Statement on Auditing Standards No. 50 letters, and the clarity of disclosures in the financial statements, including the Companys disclosures of critical accounting policies and other disclosures under Managements Discussion and Analysis of Financial Conditions and Results of Operations. |
| Review, or establish standards for the type of information and the type of presentation of such information to be included in, earnings press releases and earnings guidance provided to analysts and rating agencies. |
4
| Discuss with management and independent registered public accounting firm any changes in Companys critical accounting principles and the effects of alternative GAAP methods, off-balance sheet structures and regulatory and accounting initiatives. |
| Review material pending legal proceedings involving the Company and other contingent liabilities. |
| Meet, periodically, with the CEO, CFO, the senior internal auditing executive and the independent registered public accounting firm in separate executive sessions to discuss results of examinations. In connection with and prior to giving their required certifications, the CEO and CFO must disclose to the auditors and the Committee all significant deficiencies and material weaknesses in the design or operation of internal controls, and any fraud that involves management or other employees who have a significant role in the companys internal controls. |
| Discuss with independent registered public accounting firm the matters required to be communicated to audit committees in accordance with Statement on Auditing Standards No. 114. |
| Establish procedures for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submissions by employees or contractors of concerns regarding questionable accounting or accounting matters. |
| Review periodically with the Companys management, independent auditors and outside legal counsel (i) legal and regulatory matters which may have a material effect on the financial statements, and (ii) corporate compliance policies or codes of conduct, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding the Companys financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
| Establish policies for the hiring of employees and former employees of the independent registered public accounting firm. |
2. Other Responsibilities
In addition to the foregoing, the Audit Committee shall:
| Review adequacy of this audit committee charter annually and submit charter to Board of Directors for approval. |
| Prepare report for inclusion in the Companys annual proxy statement as required by the rules of the Securities and Exchange Commission. |
| Put in place an appropriate control process for reviewing and approving Companys internal transactions and accounting. |
| Review and approve all transactions between the Company and related parties or affiliates of the officers of the Company requiring disclosure under Item 404 of Regulation S-K prior to the Company entering into such transactions. |
5
| In consultation with the Nominating and Corporate Governance Committee, maintain a Code of Conduct applicable to all employees and directors of the Company, which meets the requirements of Item 406 of the SECs Regulation S-K and the rules of Nasdaq, and provide for and review prompt disclosure to the public of any change in, or waiver of, such Code of Conduct. Review such Code of Conduct periodically and recommend such changes to such Code of Conduct as the Committee, together with the Nominating and Corporate Governance Committee, shall deem appropriate, and adopt procedures for monitoring and enforcing compliance with such Code of Conduct. |
| Report recommendations to the Board on a regular basis and present to the Board of Directors an annual performance evaluation of the Committee. |
| Perform any other activities consistent with the Charter, Bylaws and governing law as the Board of Directors or the Audit Committee shall deem appropriate, including holding meetings with the Companys investment bankers and financial analysts. |
Effectiveness
Adopted by the Board of Directors on March 12, 2024.
6
Exhibit 99.2
QT IMAGING HOLDINGS, INC.
COMPENSATION COMMITTEE CHARTER
Role
The role of the Compensation Committee (the Committee) is to discharge the responsibilities of the Board of Directors (the Board) of QT Imaging Holdings, Inc. (the Company) relating to compensation of the Companys executives, to issue an annual report on executive compensation for inclusion in the Companys proxy statement, and to oversee and advise the Board on the adoption of policies that govern the Companys compensation programs, including stock and benefit plans.
Membership
The membership of the Committee consists of at least three directors, each of whom is to be free of any relationship that, in the opinion of the Board and in accordance with the Nasdaq Stock Market LLC (the Nasdaq) listing standards, would interfere with his or her exercise of independent judgment. The Board shall affirmatively determine the independence of all Committee members in accordance with the Nasdaq listing standards, considering all factors specifically relevant to determining whether a director has any relationship to the Company that is material to that Directors ability to be independent from management in connection with the duties of a Committee member, including, but not limited to, the source of the directors compensation, including any consulting, advisory or other compensatory fee paid to such director by the Company, and the directors affiliation with the Company, or a subsidiary or affiliate thereof. Each member of the Committee shall be a non-employee director within the meaning of Rule 16b-3 under the Securities Exchange Act of 1934. All members shall be elected annually by the Board. The Board shall appoint a chairperson.
Operations
The Committee will normally meet two times per year, or on a more or less frequent basis as necessary to carry out its responsibilities. The Committee will cause to be kept adequate minutes of all its proceedings, and will report its actions to the next meeting of the Board. Committee members will be furnished with copies of the minutes of each meeting and any action taken by unanimous consent. The Compensation Committee is governed by the same rules regarding meetings (including meetings by conference telephone or similar communications equipment), action without meetings, notice, waiver of notice, quorum and voting requirements and removal and vacancies as are applicable to the Board. The Committee is authorized to adopt its own rules of procedure not inconsistent with (a) any provision of this Charter, (b) any provision of the Bylaws of the Company, or (c) the laws of the state of Delaware.
Authority
In order to fulfill its role, the Committee shall have the power to:
| Adopt, administer, amend or terminate compensation plans applicable to any class of employees of the Company and/or any subsidiary of the Company; provided that no adoption, amendment or termination of any compensation plan under which stock may be issued, or in which a member of the Board may be a participant, shall be effective unless the same shall be approved by the Board and, to the extent required by law, by the stockholders; provided, further, that no adoption, amendment or termination of any compensation plan may be made that violates this or any other committee charter of the Company; and |
| When it is determined by the Committee that a consulting firm (or other expert) is to assist in the assessment of the CEO or other senior executive officer compensation, the Committee shall have the sole authority to retain and terminate such firm or experts and have the authority to approve the consulting firm or other experts fee and other retention terms. The Committee shall also have the authority to retain legal, accounting or other experts that it determines to be necessary to carry out its duties and to determine compensation for such advisors. Any communications between the Committee and legal counsel in the course of obtaining legal advice will be considered privileged communications of the Company and the Committee will take all necessary steps to preserve the privileged nature of those communications. The Company must provide for appropriate funding, as determined by the Committee for the payment of reasonable fees to any such consultant, legal counsel or other adviser retained by the Committee. |
| The Committee has the authority to delegate any of its responsibilities to another committee, officer and/or subcommittees, as the Committee may deem appropriate in its sole discretion, subject to applicable law, rules, regulations and Nasdaq listing standards. |
Responsibilities
The principal responsibilities and functions of the Compensation Committee are as follows:
| Review the performance of the Chief Executive Officer (CEO) and executive management. |
| Assist the Board in developing and evaluating potential candidates for executive positions (including CEO). |
| Review and approve goals and objectives relevant to the CEO and other executive officer compensation, evaluate the CEOs and other executive officers performance in light of these corporate goals and objectives, and set CEO and other executive officer compensation levels consistent with its evaluation and the company philosophy. |
| Approve the salaries, bonus and other compensation for all executive officers. |
| Review and approve compensation packages for new corporate officers and termination packages for corporate officers as requested by management. |
| Review and discuss with the Board and senior officers plans for officer development and corporate succession plans for the CEO and other senior officers. |
| Review and make recommendations concerning executive compensation policies and plans. |
2
| Review and recommend to the Board the adoption of or changes to the compensation of the Companys directors. |
| Review and approve the awards made under any executive officer bonus plan, and provide an appropriate report to the Board. |
| Review and make recommendations concerning long-term incentive compensation plans, including the use of stock options and other equity-based plans. Except as otherwise delegated by the Board, the Committee will act on behalf of the Board as a Plan Administrator or similar function established to administer equity-based and employee benefit plans, and as such will discharge any responsibilities imposed on the Committee under those plans, including making and authorizing grants, in accordance with the terms of those plans. |
| Approve all special perquisites, special cash payments and other special compensation and benefit arrangements for the Companys executive officers and employees. |
| Review periodic reports from management on matters relating to the Companys personnel appointments and practices. |
| Assist management in complying with the Companys proxy statement and annual report disclosure requirements. |
| Issue an annual Report of the Compensation Committee on Executive Compensation for the Companys annual proxy statement in compliance with applicable Securities and Exchange Commission (SEC) rules and regulations. |
| Annually evaluate the Committees performance and this Charter and recommend to the Board any proposed changes to the Charter or the Committee. |
| Undertake all further actions and discharge all further responsibilities imposed upon the Committee from time to time by the Board, the federal securities laws or the rules and regulations of the SEC. |
Oversight of Compensation Consultant, Legal Counsel, or Adviser
Whenever the Committee chooses to retain or obtain the advice of a compensation consultant, legal counsel or other adviser, then except as specified in the Nasdaq listing standards, the Committee may select such consultant, legal counsel or other adviser to the Committee only after taking into consideration all factors relevant to that persons independence, including the following:
| The provision of other services to the Company by the entity that employs the compensation consultant, legal counsel or other adviser. |
| The amount of fees received from the Company by the entity that employs the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of such entity. |
| The policies and procedures of the entity that employs the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest. |
| Any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee. |
| Any stock of the Company owned by the compensation consultant, legal counsel or other adviser. |
| Any business or personal relationship of the compensation consultant, legal counsel, other adviser or the entity that employs the consultant, legal counsel or other adviser with an executive officer of the Company. |
3
With regard to any compensation consultant or other adviser identified or to be identified in the Companys proxy statement, the Committees duties and responsibilities shall include reviewing whether the retention of such consultant or adviser, or work performed or to be performed by such consultant or adviser raises any conflict of interest and, if so, to determine how to address such conflict of interest.
Effectiveness
Adopted by the Board of Directors on March 12, 2024.
4
Exhibit 99.3
QT IMAGING HOLDINGS, INC.
NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER
Role
The Nominating and Corporate Governance Committee (the Committee) is responsible for considering and making recommendations to the Board of Directors (the Board) concerning the appropriate size, functions and needs of the Board of QT Imaging Holdings, Inc. (the Company).
Membership
The Committee shall consist of three or more Directors all of whom, in the judgment of the Board, shall be independent in accordance with the listing standards of Nasdaq Stock Market, LLC (the Nasdaq).
The Chair of the Committee shall be designated by the Board, provided that if the Board does not designate a Chair, the members of the Committee, by a majority vote, may designate a Chair.
The members of the Committee shall be elected by the Board, based on the recommendation of the Committee. Each member of the Committee shall serve for such term or terms as the Board may determine or until his or her earlier resignation, removal or death. Any vacancy on the Committee shall be filled by the Board. No member of the Committee shall be removed as a member except by the Board.
Operations
The Committee shall meet at least once each year and at such other times as it deems necessary to fulfill its responsibilities. The Committee shall report regularly to the Board with respect to its activities and make recommendations to the Board as appropriate. The Committee shall maintain minutes of its meetings and records relating to those meetings.
Authority
The Committee may, at its sole discretion, engage director search firms and has the sole authority to approve the fees and other retention terms with respect to any such firms. The Committee also has the authority, as necessary and appropriate, to consult with other counsel and outside advisors to assist in its duties to the Company.
The Committee has the authority to delegate any of its responsibilities to another committee, officer and/or subcommittees, as the Committee may deem appropriate in its sole discretion, subject to applicable law, rules, regulations and Nasdaq listing standards.
Responsibilities
The following responsibilities are within the authority of the Committee and shall include, consistent with and subject to applicable law and rules and regulations promulgated by the Securities and Exchange Commission, the Nasdaq or any other applicable regulatory authority:
| Develop and recommend to the Board the criteria for Board membership. |
| Identify, consider, recruit and recommend candidates to fill new positions on the Board. |
| Review candidates recommended by stockholders. |
| Conduct the appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates. |
| Recommend director nominees for approval by the Board and election by the stockholders at the next annual meeting. |
The Committees additional functions include:
| To consider questions of possible conflicts of interest of Board members and of senior executives. |
| To monitor and recommend the functions of the various committees of the Board. |
| To recommend members and chairs of the committees. |
| To consider and make recommendations concerning appropriate size and needs of the Board. |
| To review periodically and advise on changes in Board compensation. |
| To make recommendations on the structure of Board meetings. |
| To consider matters of corporate governance and to review, at least annually, the Companys Corporate Governance Guidelines. |
| To consider director qualification standards. |
| To make recommendations with respect to director resignations. |
| To review the outside activities of senior executives. |
| To review periodically with the Chief Executive Officer the succession plans relating to positions held by elected corporate officers, and to make recommendations to the Board with respect to the selection of individuals to occupy these positions. |
| To coordinate and oversee the annual self-evaluation of the Board, its committees, individual directors and management in the governance of the Company. |
| To review on a regular basis the Companys overall corporate governance and recommend improvements, as necessary. |
| To prepare an annual performance evaluation of the Committee and annually evaluate the adequacy of its charter. |
Effectiveness
Adopted by the Board of Directors on March 12, 2024.
2